Teva and NANOLEK signed an agreement on a strategical partnership.

On 27th of September 2016 in the framework of the 13th meeting of the  Mixed Russian-Israeli Commission for Trade and Economic Cooperation under the regulation of co-chairs - Deputy Prime Minister of Russian Federation Arkady Dvorkovich and Minister of Environmental Protection of Israel Ze’ev Elkin – companies Teva and NANOLEK made an agreement on manufacturing transfer of a range of  sterile injection medicaments to Russia.

Main goals of this partnership include organizing production of sterile injection medicaments in NANOLEK’s biopharmaceutical plant, formation of new work positions, additional professional training, technology transference, including output quality control, transfer of intellectual property rights, attracting investment. Active pharmaceutical substances, produced by Teva domestically will be used in the manufacturing process.

Industrial collaboration of the two companies will start from localization of Glatiramer Acetate manufacture – an original medicament used to treat relapsing-remitting multiple sclerosis (RRMS). Glatiramer Acetate is included in the list of Vital Drugs and is being purchased by Russian Ministry of Health within the confines of government policy “Seven Nosologies” since 2008. First commercial dispatches of the prepared medicament are scheduled for 2nd quarter of 2017. Entering the full production cycle is expected in 4th quarter of 2018. Glatiramer Acetate manufacturing is the first transfer within the framework of a long-term partnership with NANOLEK.

Anna Yarvits, SVP General Manager of Teva in Russia, Ukraine and CIS noted: “Teva is the largest Israeli investor in Russian economy. Within the framework of a long-term strategy of the company’s development in Russian Federation a consecutive localization of the most demanded drugs manufacture is currently being executed. A solid dosage form drug factory Teva in Yaroslavl is currently reaching a previously declared capacity of 500 million pills per year with a growth potential of one billion, including full production cycle drugs. Cooperation with NANOLEK on the subject of localization of sterile injection medicaments in pre-filled syringes is the next step in implementation of production assets’ localization strategy.  Our company spent three years looking for a partner that would meet the highly set quality requirements. Specific equipment, some of which is owned by Teva, has been installed especially for this project, which is definitely an innovation in contract production management.”

Vladimir Khristenko, the president of NANOLEK said: “We highly appreciate the willingness of our foreign partners to entrust us the production of their medicaments at our manufacturing platform in Kirov region. In collaboration with Teva we offer our partner a high quality manufacture, built and functioning strictly according to the international requirements GMP, equipped with modern machinery from world producers, set system of quality control and a solid professional team. Implementation of our mutual product will enable us to make Teva’s biotechnological medications even more available to patients in Russia and CIS countries.”

“We welcome making such agreements regarding strategical collaboration”, - said Arkady Dvorkovich, Deputy Prime Minister of Russian Federation.

 

Teva globally

Teva Pharmaceutical Industries Ltd. Is one of the leaders in the world pharmaceutical industry. The company, with headquarters located in Israel, daily offers high quality, consumer-oriented solutions for millions of people in need of medical treatment around the world.

Teva is a leading world manufacturer of reproduced medical products. Company’s product portfolio includes more than 1000 molecules and allows to produce a wide range of reproduced drugs for almost all medicine branches. Teva takes leading world positions in the area of innovative, specialized medical products used to treat central nervous system diseases, including pain. Product portfolio also includes a wide spectrum of medicaments for treating respiratory diseases. Uniting company’s abilities in production of reproduced and specialized medicaments within the framework of global research and development department allows Teva to offer new ways to satisfy consumer needs, combining pharmaceutical engineering with a range of devices, services and technologies. Teva’s profits in 2015 reached $19.7 billion. You can visit www.tevapharm.com for additional information.

 

Teva in Russia

Teva’s performance in Russia is an example of how much attention and responsibility they account for in all 60 markets they operate in. This attitude is a key component of Teva’s mission – to offer patients around the world a high quality and available medical products. Teva included Russian market in the list of prioritized for future investments.

Teva started operating in Russia in 1995 and is now one of the biggest pharmaceutical companies in Russian market with a portfolio of more than 300 products. The company’s turnover in Russia has increased tenfold in the last five years. Now there are around 1500 employees in Teva’s Russian unit.

In October 2014, Teva Ltd opened a pharmaceutical manufacturing unit in Yaroslavl within the framework of implementation of an international investment strategy. The factory, with capacity of up to 1 billion pills a year will offer its products to Russia and neighbor countries.

Throughout more than 20 years of existence in Russian market, Teva is following their main target – provision of health, safety and high living standards to patients in Russia.

www.teva.ru